bluebird bio Inc. (BLUE): Earnings per share for the last twelve months

bluebird bio, Inc. (BLUE) is a pioneer in treating rare blood disorders using unique lentiviral therapies. GURU.Markets analytics include fundamental TTM earnings per share, where the value -20.59 represents the current figure. The asset's price action currently depends on the commercialization of Lyfgenia and liquidity. To minimize laboratory errors, bluebird bio, Inc. (BLUE) is implementing robotic bioreactor scaling systems.
Bluebird Bio - analytical breakdowns and key metrics (BLUE)

Management at bluebird bio, Inc. (BLUE) is fighting for survival amid capital shortages and regulatory pressure. This metric is calculated as the ratio of total annual net income to the average number of shares outstanding. Analyzing net income per share over the last four quarters allows investors to filter out market noise and assess the actual efficiency of the business. This is critical to avoid purchasing an overvalued asset. This chart clearly demonstrates the financial resilience of bluebird bio, Inc. (BLUE) under a regime of strict austerity.